The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia

被引：22

作者：

Giannoudis, A. ^{[1
]}

Davies, A. ^{[1
]}

Harris, R. J. ^{[1
]}

Lucas, C. M. ^{[1
]}

Pirmohamed, M. ^{[2
]}

Clark, R. E. ^{[1
]}

机构：

[1] Royal Liverpool Univ Hosp, Dept Haematol Mol & Clin Canc Med, Liverpool, Merseyside, England

[2] Univ Liverpool, Dept Mol & Clin Pharmacol, Liverpool L69 3BX, Merseyside, England

来源：

LEUKEMIA | 2014年 / 28卷 / 06期

基金：

英国医学研究理事会;

关键词：

RESISTANCE; PROGRESSION; EXPRESSION; HOCT1; CELLS;

D O I：

10.1038/leu.2014.38

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

引用

页码：1360 / 1363

页数：5

共 15 条

[1]

Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia [J].

Apperley, Jane F. .

LANCET ONCOLOGY, 2007, 8 (11) :1018-1029

[2]

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet [J].

Baccarani, Michele ;

Cortes, Jorge ;

Pane, Fabrizio ;

Niederwieser, Dietger ;

Saglio, Giuseppe ;

Apperley, Jane ;

Cervantes, Francisco ;

Deininger, Michael ;

Gratwohl, Alois ;

Guilhot, Francois ;

Hochhaus, Andreas ;

Horowitz, Mary ;

Hughes, Timothy ;

Kantarjian, Hagop ;

Larson, Richard ;

Radich, Jerald ;

Simonsson, Bengt ;

Silver, Richard T. ;

Goldman, John ;

Hehlmann, Rudiger .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) :6041-6051

[3]

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump [J].

Burger, H ;

van Tol, H ;

Boersma, AWM ;

Brok, M ;

Wiemer, EAC ;

Stoler, G ;

Nooter, K .

BLOOD, 2004, 104 (09) :2940-2942

[4]

A population study showing that the advent of second generation tyrosine kinase inhibitors has improved progression-free survival in chronic myeloid leukaemia [J].

Francis, Sebastian ;

Lucas, Claire ;

Lane, Steven ;

Wang, Lihui ;

Watmough, Sarah ;

Knight, Katy ;

Bell, Jo ;

Kaleel-Rahman, Mohammed ;

Lee, Edwin ;

O'Brien, David ;

Butt, Nauman M. ;

Sadik, Walid ;

De Soysa, Lally ;

Seale, Jim R. C. ;

Salim, Rahuman ;

Clark, Richard E. .

LEUKEMIA RESEARCH, 2013, 37 (07) :752-758

[5]

Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia [J].

Giannoudis, Athina ;

Davies, Andrea ;

Lucas, Claire M. ;

Harris, Robert J. ;

Pirmohamed, Munir ;

Clark, Richard E. .

BLOOD, 2008, 112 (08) :3348-3354

[6]

Interaction of imatinib with human organic ion carriers [J].

Hu, Shuiying ;

Franke, Ryan M. ;

Filipski, Kelly K. ;

Hu, Chaoxin ;

Orwick, Shelley J. ;

de Bruijn, Ernst A. ;

Burger, Herman ;

Baker, Sharyn D. ;

Sparreboom, Alex .

CLINICAL CANCER RESEARCH, 2008, 14 (10) :3141-3148

[7]

Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate [J].

Jordanides, Niove E. ;

Jorgensen, Heather G. ;

Holyoake, Tessa L. ;

Mountford, Joanne C. .

BLOOD, 2006, 108 (04) :1370-1373

[8]

c-MYC Oncoprotein Dictates Transcriptional Profiles of ATP-Binding Cassette Transporter Genes in Chronic Myelogenous Leukemia CD34+ Hematopoietic Progenitor Cells [J].

Porro, Antonio ;

Iraci, Nunzio ;

Soverini, Simona ;

Diolaiti, Daniel ;

Gherardi, Samuele ;

Terragna, Carolina ;

Durante, Sandra ;

Valli, Emanuele ;

Kalebic, Thea ;

Bernardoni, Roberto ;

Perrod, Chiara ;

Haber, Michelle ;

Norris, Murray D. ;

Baccarani, Michele ;

Martinelli, Giovanni ;

Perini, Giovanni .

MOLECULAR CANCER RESEARCH, 2011, 9 (08) :1054-1066

[9]

Gene expression changes associated with progression and response in chronic myeloid leukemia [J].

Radich, JP ;

Dai, HY ;

Mao, M ;

Oehler, V ;

Schelter, J ;

Druker, B ;

Sawyers, C ;

Shah, N ;

Stock, W ;

Willman, CL ;

Friend, S ;

Linsley, PS .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (08) :2794-2799

[10]

Analyzing real-time PCR data by the comparative CT method [J].

Schmittgen, Thomas D. ;

Livak, Kenneth J. .

NATURE PROTOCOLS, 2008, 3 (06) :1101-1108

← 1 2 →